Mouse model of anti-RANKL discontinuation reveals reduced bone mass and quality through disruption of bone remodeling

Abstract

The discontinuation of denosumab [antibody targeting receptor activator of nuclear factor kappa B ligand (RANKL)] therapy may increase the risk of multiple vertebral fractures; however, the underlying pathophysiology is largely unknown. In patients who underwent discontinuation after multiple injections of denosumab, the levels of tartrate-resistant acid phosphatase 5b increased compared to pretreatment levels, indicating a phenomenon known as “overshoot.” The rate of decrease in bone mineral density during the withdrawal period was higher than the rate of decrease associated with aging, suggesting that the physiological bone metabolism had broken down. Overshoot and significant bone loss were also observed in mice receiving continuous administration of anti-RANKL antibody after treatment was interrupted, resembling the original pathology. In mice long out of overshoot, bone resorption recovered, but osteoblast numbers and bone formation remained markedly reduced. The bone marrow exhibited a significant reduction in stem cell (SC) antigen 1- and platelet-derived growth factor receptor alpha-expressing osteoblast progenitors (PαS cells) and alkaline phosphatase-positive early osteoblasts. Just before the overshoot phase, the osteoclast precursor cell population expands and RANKL-bearing extracellular vesicles (EVs) became abundant in the serum, leading to robust osteoclastogenesis after cessation of anti-RANKL treatment. Thus, accelerated bone resorption due to the accumulation of RANKL-bearing EVs and long-term suppression of bone formation uncoupled from bone resorption leads to the severe bone loss characteristic of denosumab discontinuation.

Keywords

Medical and Health Sciences / Clinical Sciences

References

[1] OkamotoK, et al. . Osteoimmunology: The conceptual framework unifying the immune and skeletal systems. Physiol. Rev., 2017, 97: 1295-1349.

[2] SeemanE, DelmasPD. Bone quality-the material and structural basis of bone strength and fragility. N. Engl. J. Med., 2006, 354: 2250-2261.

[3] KhoslaS, HofbauerLC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol., 2017, 5: 898-907.

[4] BekkerPJ, et al. . A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Min. Res., 2004, 19: 1059-1066.

[5] McClung, M. R. et al. Denosumab in postmenopausal women with low bone mineral density. Available from: www.nejm.org (2006).

[6] BoneHG, et al. . 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol., 2017, 5: 513-523.

[7] TsourdiE, et al. . Fracture risk and management of discontinuation of denosumab therapy: A systematic review and position statement by ECTS. J. Clin. Endocrinol. Metab., 2021, 106: 264-281.

[8] Aubry-RozierB, Gonzalez-RodriguezE, StollD, LamyO. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos. Int., 2016, 27: 1923-1925.

[9] CummingsSR, et al. . Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J. Bone Min. Res., 2018, 33: 190-198.

[10] TsuchiyaK, et al. . Analysis of three-dimensional bone mineral density and bone strength measured by quantitative computed tomography following denosumab discontinuation in a patient with postmenopausal osteoporosis. Clin. Inter. Aging, 2019, 14: 1445-1450.

[11] AnastasilakisAD, et al. . Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J. Bone Min. Res., 2017, 32: 1291-1296.

[12] FassioA, et al. . Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. Bone, 2019, 123: 191-195.

[13] BrownJP, et al. . Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off-treatment biopsy study. J. Bone Min. Res., 2011, 26: 2737-2744.

[14] Jähn-RickertK, et al. . Elevated bone hardness under denosumab treatment, with persisting lower osteocyte viability during discontinuation. Front. Endocrinol., 2020, 11: 1-13.

[15] LangdahlBL. Overview of treatment approaches to osteoporosis. Br. J. Pharm., 2021, 178: 1891-1906.

[16] FuSH, et al. . Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study. J. Intern. Med., 2021, 290: 1194-1205.

[17] BoneHG, et al. . Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab., 2011, 96: 972-980.

[18] FuruyaY, et al. . Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-κB ligand-neutralizing antibody: Evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts. J. Biol. Chem., 2011, 286: 37023-37031.

[19] JacquinC, GranDE, LeeSK, LorenzoJA, AguilaHL. Identification of multiple osteoclast precursor populations in murine bone marrow. J. Bone Min. Res., 2006, 21: 67-77.

[20] Jacome-GalarzaCE, LeeSK, LorenzoJA, AguilaHL. Identification, characterization, and isolation of a common progenitor for osteoclasts, macrophages, and dendritic cells from murine bone marrow and periphery. J. Bone Min. Res., 2013, 28: 1203-1213.

[21] CharlesJF, et al. . Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J. Clin. Invest, 2012, 122: 4592-4605.

[22] HollidayLS, PatelSS, RodyWJ, HollidaySL. Extracellular vesicles and circulating nucleic acids open access review rANKL and rANK in extracellular vesicles: surprising new players in bone remodeling. Extracell Vesicles Circ. Nucleic Acids, 2021, 2: 18-28

[23] Zhou, Z., Tao, Y., Zhao, H. & Wang, Q. Adipose extracellular vesicles: messengers from and to macrophages in regulating immunometabolic homeostasis or disorders. Front. Immunol.12, 666344 (2021).

[24] MukohiraH, et al. . Mesenchymal stromal cells in bone marrow express adiponectin and are efficiently targeted by an adiponectin promoter-driven Cre transgene. Int. Immunol., 2019, 31: 729-741.

[25] HoulihanDD, et al. . Isolation of mouse mesenchymal stem cells on the basis of expression of Sca-1 and PDGFR-α. Nat. Protoc., 2012, 7: 2103-2111.

[26] Handa, K., et al. Bone loss caused by dopaminergic degeneration and levodopa treatment in Parkinson’s disease model mice. Sci. Rep.9, 13768 (2019).

[27] OmiyaT, et al. . Sustained anti-osteoporotic action of risedronate compared to anti-RANKL antibody following discontinuation in ovariectomized mice. Bone Rep., 2020, 13. 100289

[28] Tamura, T., Yoshioka, Y., Sakamoto, S., Ichikawa, T. & Ochiya, T. Extracellular vesicles in bone homeostasis: key roles of physiological and pathological conditions. J. Bone Miner. Metab.41, 345–357 (2023).

[29] DengL, et al. . Osteoblast-derived microvesicles: A novel mechanism for communication between osteoblasts and osteoclasts. Bone, 2015, 79: 37-42.

[30] BonnetN, BourgoinL, BiverE, DouniE, FerrariS. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J. Clin. Invest, 2019, 129: 3214-3223.

[31] McDonaldMM, et al. . Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell, 2021, 184: 1330-1347.e13.

[32] IkebuchiY, et al. . Coupling of bone resorption and formation by RANKL reverse signalling. Nature, 2018, 561: 195-200.

[33] ChenX, ZhiX, WangJ, SuJ. RANKL signaling in bone marrow mesenchymal stem cells negatively regulates osteoblastic bone formation. Bone Res., 2018, 6: 1-8.

[34] Wu, S., Ohba, S. & Matsushita, Y. Single-cell RNA-sequencing reveals the skeletal cellular dynamics in bone repair and osteoporosis. Int. J. Mol. Sci.24, 9814 (2023).

[35] TrompetD, MelisS, ChaginAS, MaesC. Skeletal stem and progenitor cells in bone development and repair. J. Bone Min. Res., 2024, 39: 633-654.

[36] GreenbaumA, et al. . CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature, 2013, 495: 227-230.

[37] ChristopherMJ, LinkDC. Granulocyte colony-stimulating factor induces osteoblast apoptosis and inhibits osteoblast differentiation. JBMR, 2008, 21: 1-9

[38] TerashimaA, et al. . Sepsis-induced osteoblast ablation causes immunodeficiency. Immunity, 2016, 44: 1434-1443.

[39] Sølling, A. S., Harsløf, T. & Langdahl, B. Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J. Bone Miner. Res.36, 1245–1254 (2021).

[40] AcerboAS, CarrGL, JudexS, MillerLM. Imaging the material properties of bone specimens using reflection-based infrared microspectroscopy. Anal. Chem., 2012, 84: 3607-3613.

[41] YanoT, et al. . Effects of risedronate, alendronate, and minodronate alone or in combination with eldecalcitol on bone mineral density, quality, and strength in ovariectomized rats. Bone Rep., 2021, 14. 101061

[42] KogaT, et al. . NFAT and Osterix cooperatively regulate bone formation. Nat. Med., 2005, 11: 880-885.

[43] Negishi-KogaT, et al. . Immune complexes regulate bone metabolism through FcRγ signalling. Nat. Commun., 2015, 6: 1-14.

[44] ThéryC, AmigorenaS, RaposoG, ClaytonA. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol., 2006, 30: 1-29.

Funding

MEXT | Japan Society for the Promotion of Science (JSPS)(20K20496)

RIGHTS & PERMISSIONS

The Author(s)